NCT01500070已完成2 期
PREVENT: a Prospective, Multi-center, Monitored Trial Investigating the Implant of the Promus Everolimus-Eluting Stent System in Critically Ischemic Lesions BTK
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 8
- 主要终点
- Primary patency
研究概览
简要总结
This is a single-arm, prospective, multi-center monitored trial recruiting patients with critical limb ischemia and with one or more lesions in the arteries below the knee. The immediate and long-term (up to 12 months) outcome of the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) and the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific) will be evaluated.
In 2 Belgian centers, 3 German centers and 1 New Zealand center a total of 70 patients will be recruited. Primary endpoint is primary patency at 12 months, defined as absence of restenosis (≥50% stenosis) or occlusion within the originally treated lesion based on angiography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •General Inclusion Criteria:
- •Patient presenting with rest pain or minor tissue loss (Rutherford class 4 or 5)
- •Patient is willing to comply with specified follow-up evaluations at the specified times
- •Patient is >18 years old
- •Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
- •Patient has a projected life-expectancy of at least 12 months
- •The treating physician consider the patient eligible for below-the-knee treatment with the PROMUS ELEMENT Stent (Boston Scientific) and PROMUS ELEMENT PLUS Stent (Boston Scientific)
- •Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure
- •Angiographic Inclusion Criteria:
- •Single or multiple lesions with minimally 70% stenosis in one or more infrapopliteal arteries, including the tibiofibular trunk
- •A maximum of two focal target lesions in one or more infrapopliteal vessels
- •Length of lesion is maximally 40 mm, allowing maximally 2 planned stents to be implanted
- •Target vessel diameter visually estimated to be >2.5mm and <4.0mm
- •Guidewire and delivery system successfully traversed lesion
排除标准
- •Patient refusing treatment
- •Previously implanted stent in the artery to be treated
- •Failed PTA of target lesion/vessel less than 3 months prior to study procedure
- •The reference segment diameter is not suitable for the available stent design
- •Untreated flow-limiting inflow lesions
- •Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment
- •Any previous surgery in the target vessel (including prior ipsilateral crural bypass)
- •Aneurysm in the target vessel
- •Patient presents with renal failure, evidenced by a serum creatinine level >2.0mg/dL
- •Patient presents with platelet levels above or below normal range
- •Non-atherosclerothic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
- •Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 1-year life expectancy
- •Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
- •Septicemia or bacteremia
- •Any previously known coagulation disorder, including hypercoagulability
- •Contraindication to anticoagulation or antiplatelet therapy
- •Known allergies to stent or stent components
- •Known allergy to contrast media that cannot be adequately pre-medicated prior to the study procedure
- •Patient with known hypersensitivity to heparin, including those patients who have had a previous incidence of heparin-induced thrombocytopenia (HIT) type II
- •Currently participating in another clinical research trial
- •Angiographic evidence of intra-arterial thrombus or atheroembolism from inflow treatment
- •Target lesion access not performed by transfemoral approach.
研究组 & 干预措施
Drug-eluting stent
Experimental
Patients implanted with the PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or the PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
干预措施: Everolimus-Eluting Stent (PROMUS ELEMENT) (Device)
结局指标
主要结局
Primary patency
时间窗: 12 months
Absence of restenosis (50% stenosis) or occlusion within the originally treated lesion based on angiography.
次要结局
- Technical success(1 day post-procedure)
- Secondary patency rate(1, 6 and 12 month follow-up)
- Primary assisted patency rate(1, 6 and 12 month follow-up)
- Clinical success at follow-up(1 day, 1 month, 6 month and 12 month follow-up)
- Improvement of ankle-brachial index (ABI)(1 day, 1 month, 6 month and 12 month follow-up)
- Serious Adverse Events (SAE)(1 day, 1 month, 6 month and 12 month follow-up)
- Hemodynamic primary patency rate(1, 6 and 12 month follow-up)
- Limb-salvage(1, 6 and 12 month follow-up)
- Target lesion revascularization (TLR)(1 day, 1 month, 6 month and 12 month follow-up)
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
不适用
Investigation of the Glaukos® Trabecular Micro-Bypass System, Model iS3, in Subjects With Refractory GlaucomaGlaucomaNCT03639870Glaukos Corporation65
已完成
不适用
A Prospective, Multi-center and Randomized Controlled Trial of Tianyi Revascularization Device in Acute Ischemic StrokeAcute Ischemic StrokeThrombectomyAISLarge Vessel OcclusionNCT05496361Suzhou Zenith Vascular Scitech Co., Ltd.238
进行中（未招募）
不适用
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)Knee OsteoarthritisNCT05818150Merit Medical Systems, Inc.264
已完成
不适用
Safety and Feasibility of SurModics SurVeil (TM) Drug Coated BalloonPeripheral Vascular DiseasesPeripheral Arterial DiseaseNCT02648620SurModics, Inc.13
招募中
不适用
A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery StenosisPulmonary Artery StenosisNCT04973540Biotyx Medical (Shenzhen) Co., Ltd.82